Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

By M. Peeters, T. Price, A. Cervantes, A. Sobrero, Michel Ducreux, Y. Hotko, T. André, E. Chan, F. Lordick, C. Punt and 10 more. Journal of Clinical Oncology, 2010

976 citations recorded by the source corpus.

Subfields: Oncology

View Paper: https://www.semanticscholar.org/paper/79d4ab7793ff46ae986e005d0e46dc41c0f32f9d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Ping Wee
2. Zhixiang Wang
3. Fortunato Ciardiello

Citations in the corpus

• Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways (2017, background): “Lastly, skin toxicity remains a common side effect that frequently causes the discontinuation of the drug [397,398].”
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “90) 3 [106]”
• Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “In second-line trials, improved RR and PFS have been shown when the anti-EGFR antibodies are combined with an irinotecan-based regimen, although no survival advantage has been demonstrated, probably also because of cross-over to the antiEGFR antibodies in later lines [I, B] [35–37].”
• Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † (2017, methodology): “Methods The present pooled analyses are based on data from the randomized CRYSTAL (NCT00154102) [33], PRIME (NCT00364013) [34], PEAK (NCT00819780) [35], FIRE-3 (NCT00433927) [36, 37], 1714 | Arnold et al. Volume 28 | Issue 8 | 2017 Downloaded from https://academic.oup.com/annonc/article-abstract/28/”
• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, background): “Both EGFR antibodies, cetuximab and panitumumab, have been shown to increase RR and PFS, but not OS when combined with irinotecan-containing therapy in the second-line treatment setting [47, 65, 290] and can be considered if not used previously in the treatment of patients with RAS wild-type disease”